Instil Bio - TIL Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TIL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TIL, but not buy additional shares or sell existing shares.
View TIL analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for Instil Bio's shares. Their TIL share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 399.8% from the stock's current price.
View analysts price targets for TIL or view top-rated stocks among Wall Street analysts.

Instil Bio's stock was trading at $0.63 at the start of the year. Since then, TIL stock has increased by 37.6% and is now trading at $0.8670.
View the best growth stocks for 2023 here.

Instil Bio saw a decrease in short interest in January. As of January 15th, there was short interest totaling 3,020,000 shares, a decrease of 20.1% from the December 31st total of 3,780,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 4.5% of the shares of the company are short sold.
View Instil Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our TIL earnings forecast.

Instil Bio, Inc. (NASDAQ:TIL) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare Trust (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE).

(TIL) raised $250 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 13,900,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO.

Instil Bio trades on the NASDAQ under the ticker symbol "TIL."

Instil Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include R Kent Mcgaughy Jr and Vivo Capital Ix, Llc.
View institutional ownership trends.

Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TIL stock can currently be purchased for approximately $0.87.

Instil Bio (NASDAQ:TIL) has a market capitalization of $112.44 million and generates $140,000.00 in revenue each year. The company earns $-156,790,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

The company employs 412 workers across the globe.

Instil Bio's mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The official website for the company is www.tillcap.com. The company can be reached via phone at 972-499-3350 or via email at info@tillcap.com.